Trial · NCT06312813
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Difference in redness of Ultraviolet B induced erythema with 4% imipramine | 10 minutes post-treatment | Erythema change from baseline with 4% imipramine application in response to a low level of UVB are measured by using a mexameter device and thermal photography. |
| Primary | Difference in redness of Ultraviolet B induced erythema with 4% imipramine | 60 minutes post-treatment | Erythema change from baseline with 4% imipramine application in response to a low level of UVB are measured by using a mexameter device and thermal photography. |
| Primary | Difference in redness of Ultraviolet B induced erythema with 4% imipramine | 120 minutes post-treatment | Erythema change from baseline with 4% imipramine application in response to a low level of UVB are measured by using a mexameter device and thermal photography. |
| Primary | Difference in redness of Ultraviolet B induced erythema with 4% imipramine | 24 hours post-treatment | Erythema change from baseline with 4% imipramine application in response to a low level of UVB are measured by using a mexameter device and thermal photography. |
| Primary | Difference in redness of Ultraviolet B induced erythema with 4% amitriptyline | 10 minutes post-treatment | Erythema change from baseline with 4% amitriptyline application in response to a low level of UVB are measured by using a mexameter device and thermal photography. |
| Primary | Difference in redness of Ultraviolet B induced erythema with 4% amitriptyline | 60 minutes post-treatment | Erythema change from baseline with 4% amitriptyline application in response to a low level of UVB are measured by using a mexameter device and thermal photography. |
| Primary | Difference in redness of Ultraviolet B induced erythema with 4% amitriptyline | 120 minutes post-treatment | Erythema change from baseline with 4% amitriptyline application in response to a low level of UVB are measured by using a mexameter device and thermal photography. |
| Primary | Difference in redness of Ultraviolet B induced erythema with 4% amitriptyline | 24 hours post-treatment | Erythema change from baseline with 4% amitriptyline application in response to a low level of UVB are measured by using a mexameter device and thermal photography. |
| Secondary | Tolerability of 4% imipramine on facial skin | 10 minutes post-treatment | The tolerability of 4% imipramine on facial skin at baseline/Day 1 compared to Day 2 is measured by the Visual Analog Scale for pain and itch. \[0= no skin pain/itch; 10 = severe skin pain/itch\] |
| Secondary | Tolerability of 4% imipramine on facial skin | 60 minutes post-treatment | The tolerability of 4% imipramine on facial skin at baseline/Day 1 compared to Day 2 is measured by the Visual Analog Scale for pain and itch. \[0= no skin pain/itch; 10 = severe skin pain/itch\] |
| Secondary | Tolerability of 4% imipramine on facial skin | 120 minutes post-treatment | The tolerability of 4% imipramine on facial skin at baseline/Day 1 compared to Day 2 is measured by the Visual Analog Scale for pain and itch. \[0= no skin pain/itch; 10 = severe skin pain/itch\] |
| Secondary | Tolerability of 4% imipramine on facial skin | 24 hours post-treatment | The tolerability of 4% imipramine on facial skin at baseline/Day 1 compared to Day 2 is measured by the Visual Analog Scale for pain and itch. \[0= no skin pain/itch; 10 = severe skin pain/itch\] |
| Secondary | Tolerability of 4% amitriptyline on facial skin | 10 minutes post-treatment | The tolerability of 4% amitriptyline on facial skin at baseline/Day 1 compared to Day 2 is measured by the Visual Analog Scale for pain and itch. \[0= no skin pain/itch; 10 = severe skin pain/itch\] |
| Secondary | Tolerability of 4% amitriptyline on facial skin | 60 minutes post-treatment | The tolerability of 4% amitriptyline on facial skin at baseline/Day 1 compared to Day 2 is measured by the Visual Analog Scale for pain and itch. \[0= no skin pain/itch; 10 = severe skin pain/itch\] |
| Secondary | Tolerability of 4% amitriptyline on facial skin | 120 minutes post-treatment | The tolerability of 4% amitriptyline on facial skin at baseline/Day 1 compared to Day 2 is measured by the Visual Analog Scale for pain and itch. \[0= no skin pain/itch; 10 = severe skin pain/itch\] |
| Secondary | Tolerability of 4% amitriptyline on facial skin | 24 hours post-treatment | The tolerability of 4% amitriptyline on facial skin at baseline/Day 1 compared to Day 2 is measured by the Visual Analog Scale for pain and itch. \[0= no skin pain/itch; 10 = severe skin pain/itch\] |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06312813/registered